{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:52:41Z","timestamp":1792759961025,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jdin.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:09:04Z","timestamp":1639966144000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Norito","family":"Katoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-3942","authenticated-orcid":false,"given":"Yukihiro","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-1377","authenticated-orcid":false,"given":"Hiroyuki","family":"Murota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina D.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jdin.2021.11.001_bib1","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3390\/ijms21082671","article-title":"Atopic dermatitis: identification and management of complicating factors","volume":"21","author":"Tamagawa-Mineoka","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jdin.2021.11.001_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40413-017-0157-0","article-title":"Allergic profiles of mothers and fathers in the Japan Environment and Children\u2019s Study (JECS): a nationwide birth cohort study","volume":"10","author":"Yamamoto-Hanada","year":"2017","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.jdin.2021.11.001_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2021.11.001_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/1346-8138.15366","article-title":"Cost of illness study for adult atopic dermatitis in Japan: a cross-sectional web-based survey","volume":"47","author":"Murota","year":"2020","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2021.11.001_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcph.1550","article-title":"Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials","volume":"60","author":"Nader","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jdin.2021.11.001_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0031-x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"10139","key":"10.1016\/j.jdin.2021.11.001_bib7","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"10139","key":"10.1016\/j.jdin.2021.11.001_bib8","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.jdin.2021.11.001_bib9","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.jdin.2021.11.001_bib10","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10188","key":"10.1016\/j.jdin.2021.11.001_bib11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.jdin.2021.11.001_bib12","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jdin.2021.11.001_bib13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.jdin.2021.11.001_bib14","first-page":"891","article-title":"A phase 3, randomized, double-blind study comparing upadacitinib monotherapy to MTX monotherapy in MTX-na\u00efve patients with active rheumatoid arthritis","volume":"70","author":"van Vollenhoven","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jdin.2021.11.001_bib15","unstructured":"Common terminology criteria for adverse events (CTCAE) v4.03. National Cancer Institute. Accessed August 30, 2021. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"issue":"3","key":"10.1016\/j.jdin.2021.11.001_bib16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"10.1016\/j.jdin.2021.11.001_bib17","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis: results from 2 pivotal, phase 3, randomised, double-blind, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10290","key":"10.1016\/j.jdin.2021.11.001_bib18","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from a pivotal phase 3, randomised, double-blind, placebo-controlled study (AD Up)","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdin.2021.11.001_bib19","unstructured":"Rinvoq. (updacitinib) extended-release tablets, for oral use. AbbVie Inc. Accessed August 30, 2021. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"issue":"1","key":"10.1016\/j.jdin.2021.11.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-019-08768-3","article-title":"Eczema herpeticum: clinical and pathophysiological aspects","volume":"59","author":"Damour","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.jdin.2021.11.001_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.jdin.2021.11.001_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2021.11.001_bib23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2021.11.001_bib24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"10.1016\/j.jdin.2021.11.001_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet (London, England)"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:00:07Z","timestamp":1762981207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328721000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"alternative-id":["S2666328721000894"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2021.11.001","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}